ONAPGO (apomorphine HCL) injection, for sc infusion is a continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease patients.

ONAPGO is a dopaminergic agonist indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. (1) The extra dose may be titrated in increments of 0.5 mg or 1 mg based on clinical response and tolerability. Subsequent extra doses are between 0.5 mg and 2 mg, with at least 3 hours between extra doses and a maximum of

6 days ago · ONAPGO TM: A Newly-Approved Medication for OFF Periods in Parkinson’s. Breaking News! The first subcutaneous (under the skin) apomorphine infusion, now called ONAPGO TM, was approved by the Food and Drug Administration (FDA) on February 4, 2025. Apomorphine is a dopamine agonist whose effects have a rapid onset.

Before you start using Onapgo, tell your healthcare provider about all of your medical conditions, including: difficulty staying awake during the daytime • dizziness, fainting spells, or low blood pressure • asthma; allergies to any medicines containing sulfites • heart problems • a history of stroke or other brain problems;

ONAPGO is a prescription medicine used to treat motor fluctuations (OFF episodes) in adults with advanced Parkinson’s disease. It is not known if ONAPGO is safe and effective in children.

Feb 4, 2025 · Previously called SPN-830, Onapgo consists of a portable electronic pump that continuously delivers apomorphine via a subcutaneous infusion over 14-18 hours a day. This is intended to provide a steadier supply for better symptom control while also being less invasive, that is, requiring fewer injections, than other formulations.

6 days ago · Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed...

5 days ago · Onapgo is a small lightweight device that delivers apomorphine directly into the bloodstream, bypassing the digestive system. It mimics dopamine to help manage Parkinson’s...

Feb 4, 2025 · ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease; ONAPGO is a wearable subcutaneous ...

Because Onapgo is delivered continuously through an under-the-skin infusion, the medication bypasses the gastrointestinal track and directly enters the brain, stimulating dopamine receptors — potentially leading to more predictable symptom improvement. Researchers evaluated Onapgo in the Phase III TOLEDO clinical trial.